The House of Representatives has passed a bill that would provide prescription drug coverage under Medicare to seniors and the disabled. The bipartisan proposal calls for a public-private partnership to let senior citizens choose between competing plans for coverage that they feel best meets their needs.
The House of Representatives has passed a bill that would provide prescription drug coverage under Medicare to seniors and the disabled. The bipartisan proposal calls for a public-private partnership to let senior citizens choose between competing plans for coverage that they feel best meets their needs.
"Our plan is voluntary, affordable and available to all," said bill sponsor Rep. Bill Thomas (R-CA) when the bill was unveiled. "Those who need coverage will know that a limit is placed on out-of-pocket expenses so that they will not be forced to choose between lifesaving drugs or putting food on the table."
Thomas also said that the bill would give seniors and the disabled at least two private-sector health plans to choose from.
The proposal, which is expected to cost $40 billion over five years, will be paid for through savings brought about through Medicare reforms.
"Our prescription drug plan will be paid for with savings from eliminating the misuses of Medicare," Thomas said. "In the past four years, the Republican Congress has taken extraordinary steps to combat waste and abuse in order to save money and make Medicare more efficient for seniors and the disabled. Thanks to these efforts, in 1999 alone, over $12 billion was saved."
The insurance industry is praising the proposal as an important part of improving Medicare.
"America's seniors and individuals with disabilities deserve a Medicare program that provides a choice of high-quality health plans providing comprehensive benefits - including prescription drugs - at an affordable price," said Karen Ignagni, president and CEO of the American Association of Health Plans. "By approving a prescription drug benefit option, the U.S. House of Representatives has taken an important step forward to build on the promise made to beneficiaries at the program's inception in 1965. This debate now moves to the Senate, and we encourage a thorough examination of the proposals under consideration."
A spokesperson for the Pharmaceutical Research and Manufacturers of America, Washington, said the organization was "encouraged" by the Rx 2000 Act, but that the bill still failed to provide a comprehensive overhaul of Medicare, which PhRMA advocates. PR
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
October 23rd 2024Peter Marks, director, Center for Biologics Evaluation and Research, FDA, presented the keynote presentation on the future of gene therapy as part of the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.